Nicholas Piramal India today reported a consolidated net profit of Rs 218.05 crore for the year ended March 31, 2007 as against Rs 120.65 crore for the year ended March 31, 2006. According to a release issued by the company to the BSE today, total income moved up to Rs 2,472.32 crore in FY07 from Rs 1,622.62 crore in FY06.For the quarter ended March 31, 2007, the group posted a consolidated profit after prior period items of Rs 54.95 crore where as the same was Rs 15.17 crore in Q4FY06. Total income was Rs 645.21 crore in Q4FY07 as against Rs 433.16 crore for the quarter ended March 31, 2006.The consolidated results for the current quarter and the year ended March 31, 2007 are not strictly comparable with the results of the corresponding previous period and year ended March 31, 2006 as they:a. include the operations of NPIL Pharmaceuticals (UK) Ltd, UK and Torcan Chemical Ltd, Canada, which were acquired on December 02, 2005 for the whole year.b. include the operations of Morpeth manufacturing facility acquired from Pfizer on June 19, 2006.c. include the operations of Nicholas Piramal Consumer Products Pvt Ltd (erstwhile Boots Piramal Pvt Ltd) as wholly owned subsidiary from September 29, 2006.d. include the operations of NPIL - Dr. Phadke Pathology and Infertility Center Pvt Ltd as wholly-owned subsidiary from July 14, 2006.The board of directors of the company, which met today, approved a final dividend of 25% (i.e. Rs 0.50 per share) on 20,90,17,606 shares of Rs 2/- each."This is in addition to the interim dividend of 150% (i.e. Rs 3 per share) declared by the board on March 15, 2007. Thus, the total dividend for the financial year ended March 31, 2007 works out to 175% (i.e. Rs 3.50 per share)," the release added.
